Loading...

Oramed Pharmaceuticals Inc.

ORMPNASDAQ
Healthcare
Biotechnology
$2.13
$-0.11(-4.91%)

Oramed Pharmaceuticals Inc. (ORMP) Company Profile & Overview

Explore Oramed Pharmaceuticals Inc.’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

Oramed Pharmaceuticals Inc. (ORMP) Company Profile & Overview

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.

SectorHealthcare
IndustryBiotechnology
CEOMr. Nadav Kidron Esq.

Contact Information

844 967 2633
1185 Avenue of the Americas, New York City, NY, 10036

Company Facts

13 Employees
IPO DateMay 1, 2007
CountryUS
Actively Trading

Frequently Asked Questions